Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Charles River Laboratories International, Inc. CRL

Healthcare  —  Diagnostics & Research
292.84 (1.60) (0.54%) as of 25 Sep
Market cap
$14.1B
P/E
0.0×
S&P 500 Member Cash Flow Champion (3y) Insider Buys (last 12m)
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) EV/EBITDA

As of 25 September 2026, Charles River Laboratories International, Inc. (CRL) trades at a EV/EBITDA of 29.8×. Over the past ten years it has ranged from 9.3× (April 2025) to 33.1× (September 2021); the current reading is higher than 98% of that period. That is above the Diagnostics & Research industry median of 25.2× and above the Healthcare sector median of 10.4×.

EV/EBITDA, daily

Annual

Period EV/EBITDA Change
FY2025 19.9× 38.77%
FY2024 14.3× (7.06%)
FY2023 15.4× 8.18%
FY2022 14.3× (43.00%)
FY2021 25.0× 18.24%
FY2020 21.2× 27.84%
FY2019 16.6× 18.36%
FY2018 14.0× (5.89%)
FY2017 14.9× 14.82%
FY2016 12.9× (12.97%)

Quarterly

Period EV/EBITDA Change
Jun 2026 24.1× 29.17%
Mar 2026 18.6× (6.31%)
Dec 2025 19.9× 60.99%
Sep 2025 12.4× (0.98%)
42 more quarters

Against its own ten years

Low 9.3× High 33.1×
Ten-year median 15.0×
Current reading's percentile 98

EV/EBITDA against peers

Company EV/EBITDA
GH Guardant Health, Inc. compare n/m
TWST Twist Bioscience Corporation compare n/m
DGX Quest Diagnostics Incorporated compare 14.1×
LH Labcorp Holdings Inc. compare 14.7×
QGEN QIAGEN N.V. compare 15.3×
ICLR ICON PLC compare 23.5×
RVTY Revvity Inc. compare 24.5×
MEDP Medpace Holdings, Inc. compare 28.0×
CRL Charles River Laboratories International, Inc. 29.8×
Diagnostics & Research industry median 25.2×
Healthcare sector median 10.4×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CRL